Please login to the form below

Not currently logged in
Email:
Password:

Valeant adds Jeffrey Ubben to board

CEO of ValueAct supports takeover of Allergan

Valeant adds Jeffrey Ubben to boardValeant has appointed Jeffrey Ubben, CEO of ValueAct Capital, as a member of its board of directors.

Ubben joins at a crucial time for Valeant as the company tries to take over Allergan, the marketer of Botox and other aesthetic and health products.

The company will benefit from Ubben's rich business experience, which includes founding the investment management firm ValueAct Capital.

Ubben commented on the recent attempts to acquire Allergan, which have prompted a backlash, with Allergan questioning Valeant's business model.

“Valeant has become significantly undervalued on a standalone basis due to recent unjustified attacks on the company,” said Ubben. “We are strongly supportive of the Allergan-Valeant combination in light of their perfect strategic fit and the potential to create enormous shareholder value for both companies.”

2nd October 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics